يعرض 341 - 360 نتائج من 2,171 نتيجة بحث عن 'significantly ((altered decrease) OR (teer decrease))', وقت الاستعلام: 0.32s تنقيح النتائج
  1. 341

    Raw dataset Fig. 6. حسب Hong Zhang (25820)

    منشور في 2025
    الموضوعات:
  2. 342
  3. 343

    Table 1_Alterations in sulcal depth and associated functional connectivity in schizophrenia with auditory verbal hallucinations.docx حسب Zhenru Guo (21811247)

    منشور في 2025
    "…</p>Results<p>Schizophrenia patients with auditory verbal hallucinations exhibited significantly increased sulcal depth in left hemispheric regions including the lingual gyrus, cingulate gyrus, pericalcarine cortex, parahippocampal gyrus, superior frontal gyrus, cuneus, and precuneus, whereas decreased sulcal depth was observed in right hemispheric regions encompassing the superior parietal gyrus, superior frontal gyrus, lingual gyrus, lateral occipital cortex, fusiform gyrus, postcentral gyrus, middle frontal gyrus, precentral gyrus, inferior temporal gyrus, precuneus, and parahippocampal gyrus compared to schizophrenia patients without auditory verbal hallucinations. …"
  4. 344

    <b>Exercise alters molecular profiles of inflammation and substrate metabolism in human white adipose tissue</b> حسب Maria Pino (6944198)

    منشور في 2025
    "…In summary, short-term aerobic training significantly reduces local inflammation and increases lipid metabolism in WAT of sedentary overweight women – independent of alterations in body and fat mass. …"
  5. 345
  6. 346

    Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  7. 347

    Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  8. 348

    Table 5_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  9. 349

    Table 2_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  10. 350

    Table 3_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  11. 351
  12. 352
  13. 353
  14. 354
  15. 355
  16. 356
  17. 357
  18. 358
  19. 359
  20. 360